ds-pharma | Tokio X'press

💊Registration of Clinical Study Information and Disclosure of Clinical Study Results and Clinical Study Data

Tuesday April 3rd, 2018By Tokio X'press Pharmaceutical ds-pharma

💊Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)

Wednesday March 7th, 2018By Tokio X'press FDA, Pharmaceutical ds-pharma

💊Sumitomo Dainippon Pharma Completes Manufacturing Plant for Regenerative Medicine & Cell Therapy

Thursday March 1st, 2018By Tokio X'press IPS, Pharmaceutical ds-pharma

💊SUMITOMO DAINIPPON PHARMA CO., LTD. Filed Additional Patent Infringement Lawsuit Regarding LATUDA in the United States

Monday February 26th, 2018By Tokio X'press FDA, Pharmaceutical ds-pharma

💊FDA PHARMA TODAY

Wednesday February 14th, 2018By Tokio X'press Drugs, Pharmaceutical ds-pharma